These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11999900)

  • 1. Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat.
    Gracey DJ; Bell R; King DJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):497-504. PubMed ID: 11999900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat.
    Gracey DJ; Bell R; King DJ
    Pharmacol Biochem Behav; 2000 Mar; 65(3):459-63. PubMed ID: 10683486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of latent inhibition in the rat by the CCK antagonist proglumide.
    Gracey DJ; Bell R; King DJ; Trimble KM; McDermott BJ
    Pharmacol Biochem Behav; 1998 Apr; 59(4):1053-9. PubMed ID: 9586867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride.
    Trimble KM; Bell R; King DJ
    Pharmacol Biochem Behav; 1997 Apr; 56(4):809-16. PubMed ID: 9130309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.
    Feifel D; Reza T; Robeck S
    Neuropsychopharmacology; 1999 Feb; 20(2):141-9. PubMed ID: 9885794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI.
    Shilling PD; Feifel D
    Psychopharmacology (Berl); 2002 Nov; 164(3):285-93. PubMed ID: 12424552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli.
    Feldon J; Weiner I
    Biol Psychiatry; 1991 Apr; 29(7):635-46. PubMed ID: 2054435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
    de Tullio P; Delarge J; Pirotte B
    Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.
    Dezube M; Sugg EE; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; James MK; Johnson MF; Mosher JT
    J Med Chem; 1995 Aug; 38(17):3384-90. PubMed ID: 7650691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central effects of CCK ligands in pigs making operant responses for food.
    Parrott RF
    Pharmacol Biochem Behav; 1994 Nov; 49(3):463-9. PubMed ID: 7862695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of conditioned reward blocked by intra-accumbens infusion of PD-140548, a CCKA receptor antagonist.
    Josselyn SA; Vaccarino FJ
    Pharmacol Biochem Behav; 1996 Nov; 55(3):439-44. PubMed ID: 8951986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
    Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
    Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Several roles of CCKA and CCKB receptor subtypes in CCK-8-induced and LiCl-induced taste aversion conditioning.
    Mosher JT; Johnson MF; Birkemo LS; Ervin GN
    Peptides; 1996; 17(3):483-8. PubMed ID: 8735976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
    J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
    Gaisler-Salomon I; Weiner I
    Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDL 73,147EF, a 5-HT3 antagonist, facilitates latent inhibition in the rat.
    Moran PM; Moser PC
    Pharmacol Biochem Behav; 1992 Jul; 42(3):519-22. PubMed ID: 1409784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral axotomy influences the in vivo release of cholecystokinin in the spinal cord dorsal horn-possible involvement of cholecystokinin-B receptors.
    Gustafsson H; de Araújo Lucas G; Schött E; Stiller CO; Alster P; Wiesenfeld-Hallin Z; Brodin E
    Brain Res; 1998 Apr; 790(1-2):141-50. PubMed ID: 9593865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response.
    Felicio LF; Mazzini BK; Cacheiro RG; Cruz TN; Flório JC; Nasello AG
    Peptides; 2001 Aug; 22(8):1299-304. PubMed ID: 11457524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.